A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)

Trial Profile

A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Glomerulonephritis; Membranoproliferative glomerulonephritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
    • 12 Mar 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Aug 2019.
    • 12 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top